FDA approves AstraZeneca Farxiga new indications
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, AstraZeneca announcedThe FDA(http://approvefariga's new indications to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes with cardiovascular disease or multiple cardiovascular risk factorsThe approval is based on the results of a cardiovascular prognostictrial(http://codenamed DECLARE-TIMI 58, the largest cardiovascular prognostic study of SGLT2 inhibitors to date, including more than 17,000 patients from 33 countriesresults showed that the net of Dagreg had significantly lower cardiocardial hospitalization (hHF) or cardiovascular death by 17% compared to placebo, a finding due to a 27% significant reduction in hHF riskThe same therapeutic benefits were shown in each patient subgroupDagrenet is an oral SGLT2 inhibitor that can be used not only as a single or complementary therapy to improve blood sugar levels in patients with type 2 diabetes, but also with additional benefits of weight loss and blood pressure reduction, and is the first SGLT2 inhibitor to be approved for complementary treatment for type 1 diabetes2018, Dageli had net global sales of nearly $1.4 billionDagrenet has also been granted FDA-awarded fast-track eligibility to delay the progression of renal failure and prevent cardiovascular and kidney death risk in patients with chronic kidney disease
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
